Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 29, 2017
Final Director's Interest Notice
Dec 29, 2017
Non-executive director retirement
Dec 27, 2017
Change in substantial holding
Dec 05, 2017
Neuren announces new US patent to be granted for NNZ-2591
Nov 16, 2017
Consolidation/Split - NEU
Nov 16, 2017
Notification under Listing Rule 7.20 of share reorganisation
Oct 26, 2017
Appendix 4C - quarterly
Oct 13, 2017
Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
Oct 06, 2017
Investor presentation, 6 October 2017
Oct 05, 2017
Presentations and publication for Rett syndrome trials
1
2
3
4
5
Next
